ACE genotype and ACE inhibitor response in kidney disease: A perspective

American Journal of Kidney Diseases

Volumn 40, Issue 2, 2002, Pages 227-235

  Mayer, Gert ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Angiotensin converting enzyme (ACE) genotype; Angiotensin converting enzyme (ACE) inhibitor therapy; Pharmacogenomic; Progressive renal disease

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRILAT; MEDROXYPROGESTERONE ACETATE; PERINDOPRIL; RAMIPRIL;

BLOOD PRESSURE REGULATION; DNA POLYMORPHISM; GENE DELETION; GENE INSERTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; INTRON; KIDNEY DISEASE; PHARMACOGENOMICS; REVIEW;

EID: 0036324669     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.34489     Document Type: Article

References (84)

1. Racial differences in drug response: Altered sensitivity to and clearance of propanolol in men of Chinese descent as compared to American whites
2. Effect of genetic differences in omeprazole metabolism in cure rates for Helicobacter pylori infection and peptic ulcer
3. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
4. Role of intestinal P-glycoprotein (mdrI) in interpatient variation in the oral bioavailability of cyclosporine
5. Functional polymorphisms of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo
6. Preprescription genotyping: Not yet ready for prime time, but getting there
7. Pharmacogenomics: Translating functional genomics into rational therapeutics
8. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
9. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy
10. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
11. Angiotensin converting enzyme inhibitors and progression of nondiabetic renal disease
12. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease
13. Angiotensin-converting enzyme gene I/D polymorphism and renal disease
14. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
15. Single-drug therapy for hypertension in men - A comparison of six antihypertensive agents with placebo
16. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril
17. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis
18. Sequence variation in the human angiotensin converting enzyme
19. The relative roles of circulating and tissue renin-angiotensin systems
20. Pharmacologic interruption of the renin-angiotensin system and the kidney: Differential responses to angiotensin-converting enzyme and renin inhibition
21. Production of angiotensins I and II at tissue sites in intact pigs
22. The relevance of tissue angiotensin converting enzyme: Manifestations in mechanistic and endpoint data
23. Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme
24. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice
25. Point mutation in the stalk of angiotensin converting enzyme causes a dramatic increase in serum angiotensin converting enzyme but no cardiovascular disease
26. Regulation of angiotensin converting enzyme
27. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
28. Angiotensin converting enzyme (ACE) I/D genotype and renal ACE gene expression
29. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy
30. Angiotensin-converting enzyme in the human heart: Effect of the deletion/insertion polymorphism
31. Angiotensin I-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes
32. ACE gene polymorphism in cardiovascular disease: Meta-analysis of small and large studies in whites
33. Association between the angiotensin-converting enzyme insertion/deletion polymorphism and diabetic nephropathy: A methodologic appraisal and systematic review
34. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction
35. Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients
36. Angiotensin converting enzyme (ACE) activity levels in insulin independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy
37. Increased serum angiotensin converting enzyme activity in type I insulin-independent diabetes mellitus: Its relation to metabolic control and diabetic complications
38. Plasma angiotensin II, renin activity and serum angiotensin converting enzyme activity in non insulin dependent diabetes mellitus patients with diabetic nephropathy
39. Genetically increased angiotensin I converting enzyme level and renal complications in the diabetic mouse
40. Increased angiotensin converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome
41. Activation of the cardiac renin angiotensin system and increased myocardial collagen expression in human aortic valve disease
42. Upregulation of angiotensin converting enzyme by vascular endothelial growth factor
43. Aldosterone induces angiotensin converting enzyme gene expression in cultured neonatal rat cardiocytes
44. Prognostic value of angiotensin I converting enzyme I/D polymorphism for nephropathy in type I diabetes mellitus: A prospective study
45. Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension
46. Acute but not chronic angiotensin-converting enzyme inhibition induces enzyme synthesis in the glomerulus of the spontaneously hypertensive rat
47. Acute and chronic effects of perindopril on tissue angiotensin converting enzyme activity
48. Expression of ACE mRNA in human atrial myocardium is not dependent on left ventricular function, ACE inhibitor therapy and the ACE I/D genotype
49. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women
50. Angiotensinogen (M235T) and angiotensin converting enyzme polymorphisms in association with plasma renin and prorenin
51. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects
52. Effect of angiotensin-converting enzyme genotype on renin angiotensin components in hypertensives
53. Renal hemodynamic changes induced by captopril and angiotensin converting enzyme gene polymorphism
54. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries
55. The angiotensin-converting enzyme gene polymorphism and the responses to angiotensins and bradykinin in the human forearm
56. Vascular angiotensin-converting enzyme expression regulates local angiotensin II
57. The deletion genotype of the angiotensin I-converting enzyme is associated with an increased vascular reactivity in vivo and in vitro
58. Inhibition of tissue angiotensin converting enzyme by perindopril: In vivo assessment in the rat using radioinhibitor binding displacement
59. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects
60. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
61. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria
62. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies
63. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy
64. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study
65. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients
66. Angiotensin-converting-enzyme gene polymorphism and antiproteinuric response to renoprotective therapy
67. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy
68. Angiotensin converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease
69. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients
70. Gene-polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with primary glomerulonephritis
71. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy
72. Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy
73. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: Role of sodium status
74. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism
75. Gender affects renal vasoconstrictor response to Ang I and Ang II
76. Association of angiotensiogen gene T235 variant with progression of immunoglobulin A nephropathy in Caucasian patients
77. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors
78. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies
79. Linkage and association analysis of angiotensin I converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure
80. Evidence from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels
81. Segregation and linkage analysis of serum angiotensin I-converting enzyme levels: Evidence for two quantitative-trait loci
82. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type I antagonist treatment in hypertensive patients
83. Pharmacogenetic interactions between beta blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure